Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Non Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Interest & Investment Income (2016 - 2020)

Historic Interest & Investment Income for Summit Therapeutics (SMMT) over the last 5 years, with Q1 2020 value amounting to -$1000.0.

  • Summit Therapeutics' Interest & Investment Income fell 13840.62% to -$1000.0 in Q1 2020 from the same period last year, while for Mar 2020 it was $5841.4, marking a year-over-year increase of 10016.43%. This contributed to the annual value of -$5000.0 for FY2019, which is N/A changed from last year.
  • Per Summit Therapeutics' latest filing, its Interest & Investment Income stood at -$1000.0 for Q1 2020, which was down 13840.62% from $1237.7 recorded in Q4 2019.
  • Summit Therapeutics' Interest & Investment Income's 5-year high stood at $4.1 million during Q4 2017, with a 5-year trough of -$7.2 million in Q4 2018.
  • Moreover, its 5-year median value for Interest & Investment Income was $1645.2 (2016), whereas its average is $34271.6.
  • Data for Summit Therapeutics' Interest & Investment Income shows a peak YoY increase of 28315494.27% (in 2018) and a maximum YoY decrease of 27611.03% (in 2018) over the last 5 years.
  • Quarter analysis of 5 years shows Summit Therapeutics' Interest & Investment Income stood at $2000.0 in 2016, then crashed by 631.25% to -$10625.1 in 2017, then plummeted by 67824.13% to -$7.2 million in 2018, then soared by 100.02% to $1237.7 in 2019, then crashed by 180.8% to -$1000.0 in 2020.
  • Its Interest & Investment Income stands at -$1000.0 for Q1 2020, versus $1237.7 for Q4 2019 and $2603.7 for Q1 2019.